Incyte Corporation (INCY) Q3 2024 Earnings Call Transcript Summary
Incyte Corporation (INCY) Q3 2024 Earnings Call Transcript Summary
Opzelura net product revenues were $139 million, marking a 52% increase compared to the same quarter last year.The following is a summary of the Incyte Corporation (INCY) Q3 2024 Earnings Call Transcript:
以下是因塞特公司（INCY）2024年第三季度業績會交易簡報總結：
Financial Performance:
金融業績：
Incyte reported a 24% increase in total revenues year-over-year for Q3 2024, reaching $1.1 billion, driven by strong demand for Jakafi and Opzelura.
Jakafi net product revenue was $731 million, up 16% year-over-year.
Opzelura net product revenues were $139 million, marking a 52% increase compared to the same quarter last year.
因塞特報告稱，2024年第三季度，總營業收入同比增長24%，達到11億美元，受到Jakafi和Opzelura強勁需求的推動。
Jakafi淨產品營業收入爲73100萬美元，同比增長16%。
Opzelura淨產品營業收入達13900萬美元，較去年同期增長52%。
Business Progress:
業務進展：
FDA approved Niktimvo for chronic graft-versus-host disease, with launch expected in Q1 2025.
Positive AGAVE-201 trial results were published, supporting Niktimvo's transformative potential.
Filed an sNDA for ruxolitinib cream in pediatric atopic dermatitis with anticipation of approval in H2 2025.
Expanded commercialization of Opzelura in Europe, with $20 million in net sales during the quarter.
FDA批准了Niktimvo用於慢性移植物抗宿主病的治療，預計將於2025年第一季度推出。
發佈了AGAVE-201試驗的積極結果，支持Niktimvo的轉型潛力。
已提交小兒特應性皮炎益普利替尼乳膏的sNDA，並預計在2025年下半年獲批。
在歐洲擴大了Opzelura的商業化，本季度淨銷售額爲$2000萬。
Opportunities:
機會：
Jakafi sales growth opportunities driven by diverse indications such as myelofibrosis, polycythemia vera, and graft-versus-host disease, expecting the largest contribution from PV over time.
Opportunities for new revenue streams from anticipated product launches including tafasitamab for follicular lymphoma and retifanlimab for SCAC in 2025.
由於疾病的多樣性顯示，Jakafi在包括骨髓纖維化、紅細胞增多症和移植物抗宿主病在內的各種適應症上存在增長機會，預計隨着時間的推移，PV將爲其貢獻最大。
預計通過包括用於濾泡性淋巴瘤的tafasitamab和用於SCAC的retifanlimab等產品的上市，將帶來新的營業收入來源。
Risks:
風險：
Anticipated slow growth from certain AI services as they scale and reach general availability.
Potential regulatory risks associated with the approval of new products and smaller vial sizes for Niktimvo.
隨着規模擴大並逐漸普及，預計某些人工智能服務的增長速度將緩慢。
與新產品的批准以及Niktimvo小瓶規格有關的潛在監管風險。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
